---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-017945"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:21:50.564536+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enGene expands loan facility to $125M; draws $25M initial tranche with Hercules Capital

## Summary
- Second Amendment increases term loan facility from $50M to up to $125M, with initial $25M advance to refinance prior debt.
- New loans mature January 1, 2030; interest rate is prime + 2.25% (min 9.25%, capped at 10.25%).
- End-of-term fee of 5.95% of aggregate principal; additional tranches tied to clinical, approval, and commercial milestones.
- Issued 40,850 warrants at $9.18/share to Lenders as part of initial draw; up to 204,248 warrants possible if fully drawn.
- Loan secured by substantially all assets including intellectual property; Hercules Capital acts as agent.

## SEC filing metadata
- accession: 0001193125-26-017945
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/0001193125-26-017945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/engn-20260120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-017945
- JSON: https://secwatch.observer/filing/0001193125-26-017945.json
- Plain text: https://secwatch.observer/filing/0001193125-26-017945.txt

## Key facts
- Debt Financings
  enGene Therapeutics Inc. incurred term loan of up to $125 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2030.
  - Instrument: term loan
  - Principal: up to $125 million
  - Counterparty: Hercules Capital, Inc.
  - Rate: greater of (a) the prime rate of interest as reported in the Wall Street Journal
  - Maturity: January 1, 2030
  - Event: incurrence
  source text: The Amended Loan Agreement provides for up to $125 million available for advances in multiple tranches (the “2026 Term Loans”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/0001193125-26-017945-index.htm
- Debt Financings
  enGene Therapeutics Inc. incurred term loan of $25 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2030.
  - Instrument: term loan
  - Principal: $25 million
  - Counterparty: Hercules Capital, Inc.
  - Rate: greater of (a) the prime rate of interest as reported in the Wall Street Journal
  - Maturity: January 1, 2030
  - Event: incurrence
  source text: The Amended Loan Agreement provides for up to $125 million available for advances in multiple tranches (the “2026 Term Loans”), as follows: (i) an initial term loan advance (the “2026 Tranche 1 Advance”) of $25 million to refinance in full the term loans outstanding under the Prior Loan Agreement, which advance was issued to the Borrower on the Closing Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/0001193125-26-017945-index.htm
- Equity Issuances
  enGene Therapeutics Inc. issued 40,850 2026 Warrants of warrant to Lenders (Hercules Capital, Inc. and others).
  - Security: warrant
  - Shares: 40,850 2026 Warrants
  - Purchaser: Lenders (Hercules Capital, Inc. and others)
  source text: On the Closing Date, the Company issued to the Lenders an aggregate number of 40,850 2026 Warrants reflecting each Lender’s pro rata commitments under the Amended Loan Agreement in connection with the 2026 Tranche 1 Advance (the “2026 Closing Date Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/0001193125-26-017945-index.htm
- Material Agreements
  enGene Therapeutics Inc. entered into Second Amendment with Hercules Capital, Inc. valued at up to $125 million (effective 2026-01-20).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: up to $125 million
  - Effective: 2026-01-20
  source text: On January 20, 2026 (the “Closing Date”), enGene Holdings Inc. (the “Company”, and together with its subsidiaries enGene Inc. and enGene USA, Inc., collectively, the “Borrower”) entered into a Second Amendment (the “Second Amendment”) to its Amended and Restated Loan and Security Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526017945/0001193125-26-017945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.